Eli Lilly invests additional $5.3B for production of diabetes, obesity drugs in Indiana
Since scoring approval two years ago for its next-generation diabetes treatment Mounjaro (tirzepatide), Eli Lilly has been playing catch up with market leader Novo Nordisk. | Eli Lilly will invest an additional $5.3 billion in its sprawling construction project in Lebanon, Indiana, where it is building a massive manufacturing complex. The expenditure brings the company’s investment in the facility to $9 billion. The project will boost production of active pharmaceutical ingredient (API) for Lilly’s injected tirzepatide products Mounjaro, for type 2 diabetes, and Zepbound, for obesity.